Skip to main content
SpringerLink
Log in

High-density lipoprotein/apolipoprotein A-I infusion therapy

  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Strategies to decrease the progression and burden of atherosclerosis by capitalizing on the protective effect of high-density lipoprotein (HDL) and/or apolipoprotein A1 (apoA-I) levels remain active. Although efforts to raise HDL through the administration of oral agents are still being pursued, the disappointing results demonstrated with torcetrapib, an agent that elevated serum HDL and apoA-I levels through the inhibition of cholesterol ester transfer protein, have raised questions regarding this approach. An alternate strategy that consists of short-term infusions of reconstituted HDL or apoA-I is currently under evaluation. Several infusion compounds have been evaluated in clinical trials that utilize cardiovascular imaging technologies and biomarkers to assess potential clinical efficacy. Although these compounds are still in early-stage development, the results of these trials have supported the viability of this line of investigation. This review addresses the potential of HDL and/or apoA-I infusions as a possible therapeutic strategy for the treatment of coronary artery disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. 4S Investigators: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383–1389.

    Google Scholar 

  2. Shepherd J, Cobbe SM, Ford I, et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333:1301–1307.

    Article  PubMed  CAS  Google Scholar 

  3. Murray C, Lopez A: Global patterns of cause of death and burden of disease in 1990, with projections to 2020. Investing in Health Research and Development. Report of the Ad Hoc Committee on Health Research Relating to Future Intervention Options. Geneva: World Health Organization; 1996.

    Google Scholar 

  4. Gordon T, Castelli WP, Hjortland MC, et al.: High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977, 62:707–714.

    Article  PubMed  CAS  Google Scholar 

  5. Boden WE: High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol 2000, 86:19L–22L.

    Article  PubMed  CAS  Google Scholar 

  6. Krause BR, Auerbach BJ: Reverse cholesterol transport and future pharmacological approaches to the treatment of atherosclerosis. Curr Opin Investig Drugs 2001, 2:375–381.

    PubMed  CAS  Google Scholar 

  7. Alagona C, Soro A, Westerbacka J, et al.: Low HDL cholesterol concentration is associated with increased intima-media thickness independent of arterial stiffness in healthy subjects from families with low HDL cholesterol. Eur J Clin Invest 2003, 33:457–463.

    Article  PubMed  CAS  Google Scholar 

  8. Gotto AM, Whitney E, Stein EA, et al.: Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000, 101:477–484.

    PubMed  CAS  Google Scholar 

  9. Moberg B, Wallentin L: High density lipoprotein and other lipoproteins in normolipidaemic and hypertriglyceridaemic (type IV) men with coronary artery disease. Eur J Clin Invest 1981, 11:433–440.

    Article  PubMed  CAS  Google Scholar 

  10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486–2497.

    Article  Google Scholar 

  11. Frohlich JJ, Pritchard PH: The clinical significance of serum high density lipoproteins. Clin Biochem 1989, 22:417–423.

    Article  PubMed  CAS  Google Scholar 

  12. Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999, 341:410–418.

    Article  PubMed  CAS  Google Scholar 

  13. Downs JR, Clearfield M, Weis S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998, 279:1615–1622.

    Article  PubMed  CAS  Google Scholar 

  14. Verdery RB: Reverse cholesterol transport from fibroblasts to high density lipoproteins: computer solutions of a kinetic model. Can J Biochem 1981, 59:586–592.

    Article  PubMed  CAS  Google Scholar 

  15. Davis RA, Helgerud P, Dueland S, Drevon CA: Evidence that reverse cholesterol transport occurs in vivo and requires lecithin-cholesterol acyltransferase. Biochem Biophys Acta 1982, 689:410–414.

    Article  PubMed  CAS  Google Scholar 

  16. Brewer HB: HDL metabolism and the role of HDL in the treatment of high-risk patients with cardiovascular disease. Curr Cardiol Rep 2007, 9:468–492.

    Article  Google Scholar 

  17. Dimayuga P, Zhu J, Oguchi S, et al.: Reconstituted HDL containing human apolipoprotein A-1 reduces VCAM-1 expression and neointima formation following periadventitial cuff-induced carotid injury in apoE null mice. Biochem Biophys Res Commun 1999, 264:465–468.

    Article  PubMed  CAS  Google Scholar 

  18. Barter PJ, Baker PW, Rye KA: Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells. Curr Opin Lipidol 2002, 13:285–288.

    Article  PubMed  CAS  Google Scholar 

  19. Nicholls SJ, Cutri B, Worthley SG, et al.: Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 2005, 25:2416–2421.

    Article  PubMed  CAS  Google Scholar 

  20. Mackness JI, Arrol S, Abbott C, Durrington PN: Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993, 104:129–135.

    Article  PubMed  CAS  Google Scholar 

  21. Marathe GK, Zimmerman GA, McIntyre TM: Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles. J Biol Chem 2002, 278:3937–3947.

    Article  PubMed  Google Scholar 

  22. Mineo C, Deguchi H, Friffin JH, Shaul PW: Endothelial and antithrombotic actions of HDL. Circ Res 2006, 98:1352–1364.

    Article  PubMed  CAS  Google Scholar 

  23. Tso C, Martinic G, Fan WH, et al.: High-density lipoproteins enhance progenitor-mediated endothelium repair in mice. Arterioscler Thromb Vasc Biol 2006, 26:1144–1149.

    Article  PubMed  CAS  Google Scholar 

  24. The SYMPHONY Investigators: Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes. Lancet 2000, 355:337–345.

    Article  Google Scholar 

  25. Orekhov AN, Misharin Ay, Tertov VV, et al.: Artificial HDL as an anti-atherosclerotic drug. Lancet 1984, 2:1149–1150.

    Article  PubMed  CAS  Google Scholar 

  26. Badimon JJ, Badimon L, Galvez A, et al.: High density lipoprotein plasma fraction inhibits fatty streaks in cholesterol-fed rabbits. Lab Invest 1989, 60:455–461.

    PubMed  CAS  Google Scholar 

  27. Badimon JJ, Badimon L, Fuster V: Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 1990, 85:1234–1241.

    Article  PubMed  CAS  Google Scholar 

  28. Miyazaki A, Sakuma S, Morikawa W, et al.: Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol 1995, 15:1882–1888.

    PubMed  CAS  Google Scholar 

  29. Ameli S, Hultgardh-Nilsson A, Cercek B, et al.: Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Circulation 1994, 90:1935–1941.

    PubMed  CAS  Google Scholar 

  30. Soma MR, Donetti E, Parolini C, et al.: Recombinant apolipoprotein A-I Milano dimer inhibits carotid intimal thickening induced by perivascular manipulation in rabbits. Circ Res 1995, 76:405–411.

    PubMed  CAS  Google Scholar 

  31. Shah PK, Nilsson J, Kaul S, et al.: Effects of recombinant apolipoprotein A-I Milano on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation 1998, 97:780–785.

    PubMed  CAS  Google Scholar 

  32. Shah PK, Yano J, Reyes O, et al.: High-dose recombinant apolipoprotein A-I Milano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice. Potential implications for acute plaque stabilization. Circulation 2001, 103:3047–3050.

    Article  PubMed  CAS  Google Scholar 

  33. Chiesa G, Monteggia E, Marchesi M, et al.: Recombinant apolipoprotein A-I Milano infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circ Res 2002, 90:974–980.

    Article  PubMed  CAS  Google Scholar 

  34. Eriksson M, Carlson LA, Mietinnen TA, Angelin B: Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I: Potential reverse cholesterol transport in humans. Circulation 1999, 100:594–598.

    PubMed  CAS  Google Scholar 

  35. Nanjee MN, Cooke CJ, Garvin R, et al.: Intravenous apo A-1/lecithin discs increase pre-beta HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. J Lipid Res 2001, 42:1586–1593.

    PubMed  CAS  Google Scholar 

  36. Kujiraoka T, Nanjee MN, Oka T, et al.: Effects of intravenous apolipoprotein A-I phosphatidyl choline discs on LCAT, PLTP, and CETP in plasma and peripheral lymph in humans. Arterioscler Thromb Vasc Biol 2003, 23:1653–1659.

    Article  PubMed  CAS  Google Scholar 

  37. Spieker LE, Sudano I, Hurlimann D, et al.: High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 2002, 105:1399–1402.

    Article  PubMed  CAS  Google Scholar 

  38. Nissen SE, Tsunodo T, Tuzcu EM, et al.: Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes. JAMA 2003, 290:2292–2300.

    Article  PubMed  CAS  Google Scholar 

  39. Tardif JC, Gregoire J, L’Allier PL, et al.: Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007, 297:1675–1682.

    Article  PubMed  Google Scholar 

  40. Cote G, Tardif JC, Lesperance J, et al.: Effects of probucol on vascular remodeling after coronary angioplasty. Circulation 1999, 99:30–35.

    PubMed  CAS  Google Scholar 

  41. Waters D, Higginson L, Gladstone P, et al.: Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994, 89:959–968.

    PubMed  CAS  Google Scholar 

  42. Jukema JW, Bruschke AV, van Boven AJ, et al.: Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995, 91:2528–2540.

    PubMed  CAS  Google Scholar 

  43. Waters D, Crave TE, Lesperance J: Prognostic significance of progression of coronary atherosclerosis. Circulation 1993, 87:1067–1075.

    PubMed  CAS  Google Scholar 

  44. Schwartz GG, Olsson AG, Ezekowitz MD, et al.; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001, 285:1711–1718.

    Article  PubMed  CAS  Google Scholar 

  45. Dupuis J, Tardif JC, Cernacek P, Theroux P: Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) trial. Circulation 1999, 99:3227–3233.

    PubMed  CAS  Google Scholar 

  46. deGrooth GJ, Kulvenhoven JA, Stalenhoef AF, et al.: Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 2002, 105:2159–2165.

    Article  CAS  Google Scholar 

  47. Clark RW, Sutfin TA, Ruggeri RB, et al.: Raising high density lipoprotein in humans through inhibition of cholesteryl ester protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 2004, 24:490–497.

    Article  PubMed  CAS  Google Scholar 

  48. Nissen SE, Tardif JC, Nicholls SJ, et al.; ILLUSTRATE Investigators: Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007, 356:1304–1316.

    Article  PubMed  CAS  Google Scholar 

  49. Kastelein JJ, van Leuven SI, Burgess L, et al.: Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007, 356:1620–1630.

    Article  PubMed  CAS  Google Scholar 

  50. Bots ML, Visseen FL, Evans GW, et al.: Radiance 2 investigators. Lancet 2007, 370:153–160.

    Article  PubMed  CAS  Google Scholar 

  51. Barter PJ, Caulfield M, Eriksson M, et al.: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357:2109–2122.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Montreal Heart Institute and Université de Montréal, 5000 Belanger Street, Montreal, Quebec, H1T 1C8, Canada

    Jean-Claude Tardif

Authors
  1. Jean-Claude Tardif
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Therese Heinonen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stephane Noble
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean-Claude Tardif.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tardif, JC., Heinonen, T. & Noble, S. High-density lipoprotein/apolipoprotein A-I infusion therapy. Curr Atheroscler Rep 11, 58–63 (2009). https://doi.org/10.1007/s11883-009-0009-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-009-0009-7

Keywords

Search

Navigation